{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:02:10Z","timestamp":1789182130605,"version":"build-2803163510"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Postbiotica provided PostbiotiX-Restore"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Abemaciclib-induced diarrhea is a relevant concern in clinical practice. Postbiotics have emerged as a promising option for managing it.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective-prospective, 2-group, observational study to assess the impact of the postbiotic PostbiotiX-Restore, derived by Lactobacillus paracasei CNCM I-5220, on abemaciclib-induced diarrhea in patients with hormone receptor-positive HER2-negative breast cancer. The prospective population (Postbio group) received postbiotic during the first cycle of abemaciclib, while the retrospective one received standard care (Standard group). Diarrhea grading was defined according to the National Cancer Institute\u2019s Common Terminology Criteria for Adverse Events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>During the first cycle, diarrhea occurred in 78.9% of patients in the Standard cohort and 97.1% in the Postbio one, with most cases being G1-G2. Severe (G3) diarrhea was significantly less frequent in the Postbio group (0%) compared to the Standard one (7.9%; P\u2005=\u2005.029). Over the entire study period, while the grading difference was not statistically significant, G3 events were less frequent in the Postbio population (5.9%) than the Standard one (15.4%). Moreover, Postbio patients required fewer dose reductions due to diarrhea compared to the Standard group (P\u2005=\u2005.002). Notably, in the Postbio population, G1 and G2 events had short median durations (3 and 1 days, respectively) and, for the 2 patients experiencing G3 events during the second abemaciclib cycle (off postbiotic), diarrhea lasted only 1 day.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our study demonstrates the effect of PostbiotiX-Restore in mitigating abemaciclib-induced diarrhea, resulting in reduced severity, fewer dose reductions, and shorter duration. Further exploration and validation in larger cohorts are needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae101","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T16:05:21Z","timestamp":1716221121000},"page":"e1113-e1119","source":"Crossref","is-referenced-by-count":9,"title":["Optimizing abemaciclib-induced diarrhea management in patients with breast cancer: a pragmatic 2-group study using a postbiotic microbiota stabilizer"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3202-1933","authenticated-orcid":false,"given":"Rita","family":"De Sanctis","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , 20072 Pieve Emanuele, Milan , Italy"},{"name":"Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital , 20089 Rozzano, Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Tiberio","sequence":"additional","affiliation":[{"name":"Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital , 20089 Rozzano, Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , 20072 Pieve Emanuele, Milan , Italy"},{"name":"Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital , 20089 Rozzano, Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Gaudio","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , 20072 Pieve Emanuele, Milan , Italy"},{"name":"Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital , 20089 Rozzano, Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Benvenuti","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , 20072 Pieve Emanuele, Milan , Italy"},{"name":"Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital , 20089 Rozzano, Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Giordano","sequence":"additional","affiliation":[{"name":"Biostatistic Unit, IRCCS Humanitas Research Hospital , 20089 Rozzano, Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalba","family":"Torrisi","sequence":"additional","affiliation":[{"name":"Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital , 20089 Rozzano, Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zambelli","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , 20072 Pieve Emanuele, Milan , Italy"},{"name":"Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital , 20089 Rozzano, Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Pozzi","sequence":"additional","affiliation":[{"name":"Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital , 20089 Rozzano, Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Penna","sequence":"additional","affiliation":[{"name":"Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital , 20089 Rozzano, Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , 20072 Pieve Emanuele, Milan , Italy"},{"name":"Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital , 20089 Rozzano, Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6464-509X","authenticated-orcid":false,"given":"Maria","family":"Rescigno","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , 20072 Pieve Emanuele, Milan , Italy"},{"name":"Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital , 20089 Rozzano, Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"issue":"32","key":"2024090704210009200_CIT0001","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"issue":"25","key":"2024090704210009200_CIT0002","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2-advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"issue":"34","key":"2024090704210009200_CIT0003","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR1, HER22, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"2024090704210009200_CIT0004","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1634\/theoncologist.2019-0551","article-title":"Health-related quality of life in MONARCH 2: abemaciclib plus fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy","volume":"25","author":"Kaufman","year":"2020","journal-title":"Oncologist"},{"issue":"9","key":"2024090704210009200_CIT0005","doi-asserted-by":"crossref","first-page":"e1346","DOI":"10.1634\/theoncologist.2020-0084","article-title":"Health-related quality of life in MONARCH 3: abemaciclib plus an aromatase inhibitor as initial therapy in HR+, HER2\u2212 advanced breast cancer","volume":"25","author":"Goetz","year":"2020","journal-title":"Oncologist"},{"issue":"1","key":"2024090704210009200_CIT0006","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1002\/onco.13531","article-title":"Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3","volume":"26","author":"Rugo","year":"2021","journal-title":"Oncologist"},{"issue":"6","key":"2024090704210009200_CIT0007","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.annonc.2022.03.006","article-title":"Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study","volume":"33","author":"Rugo","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"2024090704210009200_CIT0008","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3920\/BM2012.0046","article-title":"Postbiotics: what else","volume":"4","author":"Tsilingiri","year":"2013","journal-title":"Benef Microbes"},{"key":"2024090704210009200_CIT0009","doi-asserted-by":"crossref","first-page":"1157164","DOI":"10.3389\/fmicb.2023.1157164","article-title":"Lactobacillus paracasei CNCM I-5220-derived postbiotic protects from the leaky-gut","volume":"14","author":"Algieri","year":"2023","journal-title":"Front Microbiol"},{"issue":"10","key":"2024090704210009200_CIT0010","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.ccell.2023.08.014","article-title":"Sensitizing cancer cells to immune checkpoint inhibitors by microbiota-mediated upregulation of HLA class I","volume":"41","author":"Ferrari","year":"2023","journal-title":"Cancer Cell"},{"issue":"5","key":"2024090704210009200_CIT0011","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.3390\/jcm12051775","article-title":"Sticking to the rules: outcome and success rate of guideline-based diarrhea management in metastatic breast cancer patients treated with abemaciclib","volume":"12","author":"Jacobs","year":"2023","journal-title":"J Clin Med"},{"issue":"3","key":"2024090704210009200_CIT0012","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1997.15.3.974","article-title":"Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument","volume":"15","author":"Brady","year":"1997","journal-title":"J Clin Oncol"},{"key":"2024090704210009200_CIT0013"},{"key":"2024090704210009200_CIT0014","doi-asserted-by":"crossref","first-page":"1269922","DOI":"10.3389\/fphar.2024.1269922","article-title":"The adverse events of CDK4\/6 inhibitors for HR+\/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials","volume":"15","author":"Pu","year":"2024","journal-title":"Front Pharmacol"},{"key":"2024090704210009200_CIT0015"},{"key":"2024090704210009200_CIT0016"},{"key":"2024090704210009200_CIT0017"},{"issue":"2","key":"2024090704210009200_CIT0018","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1158\/1535-7163.MCT-18-0734","article-title":"Intestinal toxicity in rats following administration of CDK4\/6 inhibitors is independent of primary pharmacology","volume":"18","author":"Thibault","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"2024090704210009200_CIT0019","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.breast.2020.10.007","article-title":"Safety and efficacy of cyclindependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia","volume":"54","author":"Fuentes-Antr\u00e1s","year":"2020","journal-title":"Breast"},{"issue":"16_suppl","key":"2024090704210009200_CIT0020","doi-asserted-by":"crossref","first-page":"e13067","DOI":"10.1200\/JCO.2023.41.16_suppl.e13067","article-title":"Feasibility of treatment with another CDK4\/6 inhibitor after severe ribociclib liver toxicity","volume":"41","author":"Zurcher","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024090704210009200_CIT0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103239","article-title":"Switching cyclin-dependent kinase inhibitors (CDK4\/6i) in patients with hormone receptor-positive (HR+)\/human epidermal growth factor-negative (HER2-) advanced breast cancer (ABC) who experienced unacceptable toxicity","author":"Benvenuti","year":"2024"},{"issue":"3","key":"2024090704210009200_CIT0022","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1078-0432.CCR-19-1425","article-title":"Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR+\/HER2- breast cancer","volume":"26","author":"Hurvitz","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"17","key":"2024090704210009200_CIT0023","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","article-title":"MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+\/HER2- metastatic breast cancer","volume":"23","author":"Dickler","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"23","key":"2024090704210009200_CIT0024","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/jnci\/djp386","article-title":"Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes","volume":"101","author":"Basch","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2024090704210009200_CIT0025","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jamaoncol.2019.5566","article-title":"Clinician vs patient reporting of baseline and postbaseline symptoms for adverse event assessment in cancer clinical trials","volume":"6","author":"Atkinson","year":"2020","journal-title":"JAMA Oncol"},{"key":"2024090704210009200_CIT0026","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.breast.2023.07.003","article-title":"Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: a randomized, open-label phase II trial (MERMAID, WJOG11318B)","volume":"71","author":"Masuda","year":"2023","journal-title":"Breast"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/9\/e1113\/59036710\/oyae101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/9\/e1113\/59036710\/oyae101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T05:05:18Z","timestamp":1725685518000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/9\/e1113\/7676645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5,20]]},"published-print":{"date-parts":[[2024,9,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae101","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,5,20]]}}}